Роль иммунотолерантности в иммуносупрессивной терапии после трансплантации печени

Автор: Аносова Е. Ю., Полудкин И. А., Казымов Б. И.

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Донорство и трансплантация органов и тканей

Статья в выпуске: 3 т.14, 2024 года.

Бесплатный доступ

Актуальность. Некоторые достижения, связанные с трансплантацией печени в области инфекционных осложнений, лечения отторжения и хирургической тактики во многом способствовали улучшению выживаемости пациентов. Тем не менее, огромный прогресс, достигнутый в области трансплантологии, в основном связан с появлением безопасных и эффективных иммуносупрессивных средств. Но осложнения от иммуносупрессивных средств все еще являются значимой проблемой и возможность отказаться от иммуносупрессантов вовсе или значительно снизить дозу поможет решить ее.

Иммунотолерантность, иммуносупрессивная терапия, трансплантация печени, отторжение трансплантата, осложнения трансплантации печени, иммунный ответ

Короткий адрес: https://sciup.org/143183283

IDR: 143183283 | DOI: 10.20340/vmi-rvz.2024.3.TX.1

Список литературы Роль иммунотолерантности в иммуносупрессивной терапии после трансплантации печени

Zhou AW, Jin J, Liu Y. Cellular strategies to induce immune tolerance after liver transplantation: Clinical perspectives. World J Gastroenterol. 2024 Apr 7;30(13):1791 -1800. https://doi.org/10.3748/wjg.v30.i13.1791. PMID: 38659486; PMCID: PMC11036497.
Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013 Jul;10:434-440.
Meirelles Júnior R.F. Salvalaggio P. Rezende MB de et al. Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015;13:149-152.
Lee JH, Lee SK, Lee HJ, Seo JM, Joh JW, Kim SJ, Kwon CH, Choe YH. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med J. 2009 Dec 31;50(6):784-8. https://doi.Org/10.3349/ymj.2009.50.6.784. Epub 2009 Dec 18. PMID: 20046418; PMCID: PMC2796404.
Lin NC, Wang HK, Yeh YC, Liu CP, Loong CC, Tsai HL, Chen CY, Chin T, Liu C. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients. J Pediatr Surg. 2015 Dec;50(12):2128-33. https://doi.Org/10.1016/j.jpedsurg.2015.08.043. Epub 2015 Aug 28. PMID: 26377868.
Wozniak L.J., Venick R.S., Naini B.V., Scapa J., Hickey M.J., Rossetti M., et al. Operational Tolerance Is Not Always Permanent: A 10-Year Prospective Study in Pediatric Liver Transplant Recipients, Liver Transplantation, Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2022.
Pérez-Escobar J, Jimenez JV, Rodríguez-Aguilar EF, Servín-Rojas M, Ruiz-Manriquez J, Safar-Boueri L, Carrillo-Maravilla E, Navasa M, García-Juárez I. Immunotolerance in liver transplantation: a primer for the clinician. Ann Hepatol. 2023 Jan-Feb;28(1):100760. https://doi.org/1 0.1016/j.aohep.2022.100760. Epub 2022 Sep 28. PMID: 36179797.
Montano-Loza AJ, Rodríguez-Pera'lvarez ML, Pageaux GP, San- chez-Fueyo A, Feng S. Liver transplantation immunology: immuno- suppression, rejection, and immunomodulation. J Hepatol. 2023 Jun;78:1199-1215.
Nakajima I, Tsukimura T, Ono T, Shiga T, Shitara H, Togawa T, Sakuraba H, Miyaoka Y. In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells. Cell Transplant. 2023 Jan-Dec;32:9636897231173734. https://doi.org/10.1177/09636897231173734. PMID: 37183961; PMCID: PMC10186575.
Safinia, Niloufar & Grageda, Nathali & Scottá, Cristiano & Thirkell, Sarah & Fry, Laura & Vaikunthanathan, Trishan & Lechler, Robert & Lom-bardi, Giovanna. (2018). Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Frontiers in Immunology. 9. 10.3389/fimmu.2018.00354.
Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol. 2021 PMID: 34343613 https://doi.org/10.1016/j.jhep.2021.07.027
Герасимова О.А., Боровик В.В., Марченко Н.В., Тилеубергенов И.И. Толерантность и минимизация иммуносупрессивной терапии после трансплантации печени. Вестник трансплантологии и искусственных органов. 2021;23(3):162-170. Gerasimova O.A., Borovik V.V., Marchenko N.V., Tileubergenov I.I. Tolerance and minimization of immunosuppressive therapy after liver transplantation. Bulletin of Transplantology and artificial organs. 2021;23(3):162-170. (In Russ). https://doi.org/10.15825/! 995-1191 -2021 -3-1 62-170
Ronca V, Wootton G, Milani C, Cain O. The immunological basis of liver allograft rejection. Front Immunol. 2020 Sep 2;11:2155.
Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012 Mar;12: 694-705.
Rodríguez-Pera'lvarez M, Germani G, Darius T, Lerut J,Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic re- view and meta-analysis. Am J Transplant. 2012 Oct;1 2:2797- 2814.
Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transplant. 2003 May 1;9:463-468.
Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant. 2008;22:502-507.
Gama JFG, Cardoso LMDF, Bisaggio RDC, Lagrota-Candido J, Henriques-Pons A, Alves LA. Immunological Tolerance in Liver Transplant Recipients: Putative Involvement of Neuroendocrine-Immune Interactions. Cells. 2022 Jul 29;11(15):2327. https://doi.org/10.3390/cells11152327. PMID: 35954171; PMCID: PMC9367574.
Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Ollinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel). 2021 Mar 31;13(7):1617. https://doi.org/10.3390/cancers13071617. PMID: 33807392; PMCID: PMC8037838.
Rodríguez-Pera'lvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013 Dec 1;59:1193-1199.
Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H. Mecha- nisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992 Jun;21(6 suppl 3):16-22.
Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014 845438.
Kirk AD. Induction immunosuppression. Transplantation. 2006 Sep 15;82:593.
Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double- blind comparative study of mycophenolate mofetil and azathio- prine in combination with cyclosporine and corticosteroids in pri- mary liver transplant recipients. Liver Transpl. 2001 May;7:442- 450.
Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010 Feb;23:155-168.
Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treat- ment for chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb;148:484-486.
Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 201 7 Dec;7:358-366.
Donnelly JP, Locke JE, MacLennan PA, et al. Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis. Clin Infect Dis. 2016 Jul 15;63:186-194.
Shepshelovich D, Tau N, Green H, et al. Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey. Transpl Infect Dis. 201 9 Oct;21.

Еще

Статья научная